SFE Investment Counsel Invests $11.41 Million in IQVIA Holdings Inc. $IQV

by · The Markets Daily

SFE Investment Counsel acquired a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 59,043 shares of the medical research company’s stock, valued at approximately $11,408,000. IQVIA makes up 1.5% of SFE Investment Counsel’s holdings, making the stock its 22nd biggest position.

Other large investors also recently added to or reduced their stakes in the company. Boston Partners bought a new stake in shares of IQVIA during the third quarter valued at approximately $676,698,000. Norges Bank bought a new position in IQVIA in the fourth quarter worth approximately $497,445,000. Victory Capital Management Inc. grew its stake in IQVIA by 2,628.1% in the fourth quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company’s stock worth $377,670,000 after purchasing an additional 1,614,063 shares in the last quarter. Orbis Allan Gray Ltd increased its holdings in IQVIA by 96.5% during the 4th quarter. Orbis Allan Gray Ltd now owns 1,901,091 shares of the medical research company’s stock worth $428,525,000 after purchasing an additional 933,554 shares during the period. Finally, AQR Capital Management LLC raised its position in IQVIA by 130.2% during the 2nd quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock valued at $245,099,000 after purchasing an additional 879,701 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Trading Down 2.2%

IQV opened at $236.18 on Friday. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The firm has a market cap of $38.87 billion, a price-to-earnings ratio of 29.30, a PEG ratio of 2.01 and a beta of 1.18. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $251.36. The stock has a fifty day moving average price of $206.65 and a 200-day moving average price of $187.09.

IQVIA (NYSE:IQV – Get Free Report) last issued its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. The company had revenue of $4.37 billion for the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The firm’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same quarter last year, the company earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, equities research analysts anticipate that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA announced that its board has authorized a share buyback program on Thursday, May 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to buy up to 6.8% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board of directors believes its shares are undervalued.

Analyst Ratings Changes

IQV has been the topic of a number of recent research reports. HSBC reissued a “buy” rating and set a $240.00 price target on shares of IQVIA in a research report on Monday, July 6th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $200.00 price objective (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. Royal Bank Of Canada increased their target price on shares of IQVIA from $221.00 to $247.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. Stifel Nicolaus raised their target price on shares of IQVIA from $220.00 to $276.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. Finally, Barclays restated an “overweight” rating on shares of IQVIA in a report on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $241.88.

Get Our Latest Analysis on IQV

Insider Activity

In related news, insider Eric Sherbet sold 5,000 shares of the stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the completion of the sale, the insider owned 20,999 shares of the company’s stock, valued at $5,232,110.84. This represents a 19.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Bhavik Patel sold 1,855 shares of the firm’s stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $235.27, for a total transaction of $436,425.85. Following the completion of the sale, the insider owned 1,348 shares of the company’s stock, valued at approximately $317,143.96. This trade represents a 57.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 12,913 shares of company stock worth $3,098,793 in the last quarter. 1.70% of the stock is currently owned by corporate insiders.

About IQVIA

(Free Report)

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

Further Reading